Our People

 

Lypanosys' management team, advisors and consultants all have many years of proven individual track records and international experience in the fields of research and drug development. Many of these individuals also have experience working with not only large companies, but also in entrepreneurial roles. This collective experience includes more than a combined 50 years of scientific research experience and a vast network of relationships with leading scientific researchers and major pharmaceutical companies around the globe.

Management Team

TONY BISHOP - EXECUTIVE CHAIRMAN
B.Com, Victoria University (Wellington); Chartered Accountant
IGlobe Treasury, Managing Partner & experienced Venture Capital Investor
Experienced Angel Investor
Completed migration and restructuring of business from New Zealand to US
Merchant Banking and Strategic Partnering


ANDREW TURNBULL - DIRECTOR
BE (Hons), University of Canterbury
Allergy Therapeutics (AIM listed specialty pharmaceutical company)
Business Development, Supply Operations, R&D & Board Director roles
Successfully opened 3 INDs with the FDA
Completed Phase I and II programs (products have since gone on to produce 2 positive phase III results)
Multiple successful pharmaceutical partnering deals, pharmaceutical business turnaround and IPO


PHILIPP D. HAAS - DIRECTOR
MBA, Banking, St. Gallen Economy, Law and Business Administration University
Investment consultant and director since 1992, with broad experience in emerging markets especially for Eastern European Countries and Turkey.
With special focus on pharmaceuticals currently Chairman of Eastpharma Ltd., group companies including Deva Holding AŞ, publicly traded Turkish pharmaceutical company.
Apart from that board memberships in various companies in Canada, New Zealand, Australia, Switzerland, US, Germany, Luxembourg and Turkey.


ROGER COLE-BAKER - DIRECTOR
B.Com, Auckland University
Chartered Accountant and member of NZ Institute of Chartered Accountants
In public practice since 1969 specializing in business valuation and forensic accounting.
Trustee of Parnell Community Trust & Chairman of Parnell Community Committee Inc
Rotarian


DR STUART MCLACHLAN - EXECUTIVE VICE PRESIDENT CLINICAL TRIALS
PH.D., University of California, Davis
Fifteen years in the US medical device and pharmaceutical Industries focusing on clinical development, project management, and strategic planning.
Global clinical development experience in the US, Europe, and Australasia
Led a large multi-functional team, within a major pharma, for global clinical development of new pharmaceuticals.
Worked with large Pharma and small blotech companies.


CONSULTANTS AND STRATEGIC R & D ADVISORS
HeteroGenelty, LLC - Washington, DC-based Scientific Management Organization, with a focus on complex and novel product categories.
Principals: Freddie Ann Hoffman, MD - CEO; Steven R. Kishter, MD, DDS - COO, with experience in the government (FDA-NIH), and global pharmaceutical industry (Pfizer;Wyeth, etc.)
Provides a team of experts in Chemistry, QAQC, Toxicology, Pharmacology, Clinical Trials, Dermatology, and Regulatory Affairs, with the FDA, Health Canada, HIH, USDA, and global pharmaceutical experience, each of whom are recognized in their respective fields.